Pembrolizumab in Treating Patients With Triple-Negative Breast CancerStatus: open
18-002 - A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy - SWOG S1418 (BR0006)
Treatment for Breast Cancer
This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
SponsorsThis trial is sponsored by SWOG.
Interested in Clinical Trial?
Providers Associated With This Trial
- Teja Poosarla, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology